Auven Therapeutics Announces Positive Results from Pivotal Clinical Trial of Seciera (OTX-101) in Dry Eye Disease

Auven Therapeutics today announced results from its Phase 2b/3 clinical trial evaluating the safety and efficacy of Seciera (OTX-101), a novel patented nanomicellar formulation of cyclosporine for the treatment of dry eye disease.

Read the full press release